Literature DB >> 8569414

In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization.

U Schmidt-Erfurth1, T Hasan, K Schomacker, T Flotte, R Birngruber.   

Abstract

BACKGROUND AND
OBJECTIVE: Photodynamic therapy (PDT) has been used successfully to occlude neovascularizations experimentally. We evaluated the vasoocclusive potential of benzoporphyrin derivative (BPD), a new photosensitizer currently in clinical trials. Since liposomally formulated BPD strongly binds to endogenous low density lipoproteins (LDL) after i.v. injection, LDL act as carrier to deliver BPD preferentially to proliferating endothelial cells. STUDY DESIGN/
MATERIALS AND METHODS: Corneal neovascularizations in rabbits were used as model. Time-dependent uptake and retention of liposomal BPD were measured in vivo by monitoring the laser-induced fluorescence (LIF). Photothrombosis was induced using a dye laser emitting at 692 nm.
RESULTS: A maximal BPD concentration was measured at 60-90 minutes postinjection determining the optimal time interval for treatment. Exposures as low as 10 J/cm2 allowed complete and irreversible neovascular occlusion as documented angiographically. Histology revealed selective endothelial damage, adjacent corneal stroma, or iris vessels, remained intact. Identical results were obtained using BPD directly complexed with LDL suggesting use of a LDL-mediated pathway.
CONCLUSION: We suggest BPD-PDT for a selective treatment of neovascular diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8569414     DOI: 10.1002/lsm.1900170207

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  15 in total

Review 1.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma.

Authors:  B Jurklies; G Anastassiou; S Ortmans; A Schüler; H Schilling; U Schmidt-Erfurth; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 3.  Ocular phototherapy.

Authors:  A D Singh
Journal:  Eye (Lond)       Date:  2012-12-14       Impact factor: 3.775

4.  Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy.

Authors:  U E Schnurrbusch; K Welt; L C Horn; P Wiedemann; S Wolf
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

5.  Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model.

Authors:  Stefan Mennel; Silvia Peter; Carsten H Meyer; Gabriele Thumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-19       Impact factor: 3.117

6.  Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models.

Authors:  C Framme; B Flucke; R Birngruber
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-27       Impact factor: 3.117

7.  Photothrombosis of corneal neovascularization by photodynamic therapy utilizing verteporfin and diode laser.

Authors:  Aziza Ahmed Hassan; Dina Foad Ghoneim; Amr Abdelraheem El-Dib; Salwa Abdelkawi Ahmed; Ahmed Medhat Abdel-Salam
Journal:  J Lasers Med Sci       Date:  2013

Review 8.  Spotlight on verteporfin in subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Application of femtosecond ultrashort pulse laser to photodynamic therapy mediated by indocyanine green.

Authors:  M Sawa; K Awazu; T Takahashi; H Sakaguchi; H Horiike; M Ohji; Y Tano
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

Review 10.  Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.